Two Sigma Advisers LP increased its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 254.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 33,000 shares of the company's stock after buying an additional 23,700 shares during the quarter. Two Sigma Advisers LP's holdings in Dr. Reddy's Laboratories were worth $521,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Royal Bank of Canada grew its stake in Dr. Reddy's Laboratories by 403.1% in the 4th quarter. Royal Bank of Canada now owns 10,037,246 shares of the company's stock valued at $158,489,000 after acquiring an additional 8,042,163 shares during the period. Renaissance Technologies LLC raised its stake in Dr. Reddy's Laboratories by 382.9% in the 4th quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock valued at $148,717,000 after purchasing an additional 7,467,979 shares during the last quarter. Aikya Investment Management Ltd lifted its holdings in Dr. Reddy's Laboratories by 416.1% in the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after purchasing an additional 4,523,303 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Dr. Reddy's Laboratories by 405.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company's stock worth $84,643,000 after purchasing an additional 4,301,212 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Dr. Reddy's Laboratories by 397.2% in the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock valued at $77,311,000 after buying an additional 3,911,404 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.
Dr. Reddy's Laboratories Trading Up 0.1%
Dr. Reddy's Laboratories stock traded up $0.02 during trading on Friday, hitting $15.55. The company had a trading volume of 743,960 shares, compared to its average volume of 1,492,198. The stock has a market cap of $12.98 billion, a price-to-earnings ratio of 24.75 and a beta of 0.33. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company's 50 day simple moving average is $13.82 and its 200-day simple moving average is $14.03. Dr. Reddy's Laboratories Limited has a 1-year low of $12.26 and a 1-year high of $16.89.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. The business had revenue of $996.17 million for the quarter, compared to analyst estimates of $83.70 billion. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
RDY has been the topic of a number of analyst reports. HSBC upgraded Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $14.44 to $16.90 in a research report on Thursday. Wall Street Zen raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Hsbc Global Res upgraded Dr. Reddy's Laboratories from a "hold" rating to a "strong-buy" rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $16.95.
Read Our Latest Stock Report on Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Company Profile
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Further Reading
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
